Get the Finder app 🥳

Track your credit score, free


How to buy Compumedics shares | A$0.4

Own Compumedics shares in just a few minutes.


Fact checked

Compumedics Limited is a medical devices business based in Australia. Compumedics shares (CMP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.4 – an increase of 8.11% over the previous week. Compumedics has a trailing 12-month revenue of around $35.1 million.

How to buy shares in Compumedics

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Compumedics. Find the share by name or ticker symbol: CMP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Compumedics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of $0.4, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of Compumedics. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Compumedics's share price?

Since the stock market crash in March caused by coronavirus, Compumedics's share price has had significant negative movement.

Its last market close was $0.4, which is 50.00% down on its pre-crash value of $0.8 and 60.00% up on the lowest point reached during the March crash when the shares fell as low as $0.25.

If you had bought $1,000 worth of Compumedics shares at the start of February 2020, those shares would have been worth $453.13 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $625.00.

Compumedics share price

Use our graph to track the performance of CMP stocks over time.

Compumedics shares at a glance

Information last updated 2020-09-25.
Latest market closeAUDA$0.4
52-week rangeAUDA$0.25 - AUDA$0.96
50-day moving average AUDA$0.4165
200-day moving average AUDA$0.4386
Target priceAUDA$1.9
PE ratio 22.7273
Dividend yield N/A (0%)
Earnings per share (TTM) AUDA$0.019

Share Trading Account Offer

IG Share Trading Offer


Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

  • Brokerage - AU shares: From AUD 5 or 0.05%
  • Brokerage - US shares: USD 0
  • Sign-up process: Instant
  • Support - After hours: Yes
Go to site
More info

Important: Share trading carries risk of capital loss.


Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD 8 or 0.1%
AUD 50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
CMC Markets Stockbroking
AUD 11 or 0.1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
ThinkMarkets Share Trading
ASX shares, ETFs
Fast sign-up: Start trading in just a few minutes
Switch between your ASX share trading account and your forex account on your mobile and access some of the lowest brokerage fees on the market with a flat $8 commission (until $200,000).
ANZ Share Investing
AUD 19.95
ASX shares, Global shares, Margin trading, Options trading
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or 0.11%
AUD 63.50 per year on the global markets account
ASX shares, Global shares, Options trading, US shares

Compare up to 4 providers

Is it a good time to buy Compumedics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Compumedics price performance over time

Historical closes compared with the close of A$0.4 on 2020-09-28

1 week (2020-09-22) 8.11%
1 month (2020-08-28) -5.88%
3 months (2020-06-29) -5.88%
6 months (2020-03-27) 33.33%
1 year (2019-09-27) -33.33%
2 years (2018-09-28) -11.11%
3 years (2017-09-28) 9.59%
5 years (2015-09-29) 50.94%

Is Compumedics under- or over-valued?

Valuing Compumedics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Compumedics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Compumedics's P/E ratio

Compumedics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Compumedics shares trade at around 23x recent earnings.

That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Compumedics's EBITDA

Compumedics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 million.

The EBITDA is a measure of a Compumedics's overall financial performance and is widely used to measure a its profitability.

Compumedics financials

Revenue TTM $35.1 million
Operating margin TTM 1.45%
Gross profit TTM $18 million
Return on assets TTM 0.86%
Return on equity TTM -23.78%
Profit margin -16.65%
Book value 0.113
Market capitalisation $71.4 million

TTM: trailing 12 months

Compumedics share dividends

We're not expecting Compumedics to pay a dividend over the next 12 months.

Compumedics share price volatility

Over the last 12 months, Compumedics's shares have ranged in value from as little as $0.25 up to $0.96. A popular way to gauge a stock's volatility is its "beta".

CMP.AU volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Compumedics's is 0.8946. This would suggest that Compumedics's shares are less volatile than average (for this exchange).

Compumedics overview

Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; ProFusion neXus 360, a Web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, and summit IP products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was founded in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.

Frequently asked questions

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site